Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

NCT04538378 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

NIH

Sponsor class

Stopped Closed due to slow accrual.

Conditions

EGFR-Mutated Non-Small-Cell Lung Carcinoma
Small Cell/Neuroendocrine

Interventions

DRUG: Olaparib
DRUG: Durvalumab
DIAGNOSTIC_TEST: EKG
PROCEDURE: Tumor biopsy
DIAGNOSTIC_TEST: CT chest, abdomen and pelvis
DIAGNOSTIC_TEST: MRI chest, abdomen and pelvis

Sponsor

National Cancer Institute (NCI)